The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program

<p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hered...

Full description

Bibliographic Details
Main Authors: Mukherjee Aparna, McGarrity Thomas J, Ruggiero Francesca, Koltun Walter, McKenna Kevin, Poritz Lisa, Baker Maria J
Format: Article
Language:English
Published: BMC 2010-11-01
Series:Hereditary Cancer in Clinical Practice
Online Access:http://www.hccpjournal.com/content/8/1/9
id doaj-5afeb05417d74f69b1b043e0502601b1
record_format Article
spelling doaj-5afeb05417d74f69b1b043e0502601b12020-11-24T21:25:58ZengBMCHereditary Cancer in Clinical Practice1897-42872010-11-0181910.1186/1897-4287-8-9The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics programMukherjee AparnaMcGarrity Thomas JRuggiero FrancescaKoltun WalterMcKenna KevinPoritz LisaBaker Maria J<p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC). These criteria were further modified in 2004 and became known as the revised Bethesda Guidelines. Our study aimed to retrospectively evaluate the percentage of patients diagnosed with HNPCC tumors in 2004 who met revised Bethesda criteria for MSI testing, who were referred for genetic counseling within our institution.</p> <p>Methods</p> <p>All HNPCC tumors diagnosed in 2004 were identified by accessing CoPath, an internal database. Both the Tumor Registry and patients' electronic medical records were accessed to collect all relevant family history information. The list of patients who met at least one of the revised Bethesda criteria, who were candidates for MSI testing, was then cross-referenced with the database of patients referred for genetic counseling within our institution.</p> <p>Results</p> <p>A total of 380 HNPCC-associated tumors were diagnosed at our institution during 2004 of which 41 (10.7%) met at least one of the revised Bethesda criteria. Eight (19.5%) of these patients were referred for cancer genetic counseling of which 2 (25%) were seen by a genetics professional. Ultimately, only 4.9% of patients eligible for MSI testing in 2004 were seen for genetic counseling.</p> <p>Conclusion</p> <p>This retrospective study identified a number of barriers, both internal and external, which hindered the identification of individuals with HNPCC, thus limiting the ability to appropriately manage these high risk families.</p> http://www.hccpjournal.com/content/8/1/9
collection DOAJ
language English
format Article
sources DOAJ
author Mukherjee Aparna
McGarrity Thomas J
Ruggiero Francesca
Koltun Walter
McKenna Kevin
Poritz Lisa
Baker Maria J
spellingShingle Mukherjee Aparna
McGarrity Thomas J
Ruggiero Francesca
Koltun Walter
McKenna Kevin
Poritz Lisa
Baker Maria J
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
Hereditary Cancer in Clinical Practice
author_facet Mukherjee Aparna
McGarrity Thomas J
Ruggiero Francesca
Koltun Walter
McKenna Kevin
Poritz Lisa
Baker Maria J
author_sort Mukherjee Aparna
title The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
title_short The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
title_full The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
title_fullStr The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
title_full_unstemmed The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
title_sort revised bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
publisher BMC
series Hereditary Cancer in Clinical Practice
issn 1897-4287
publishDate 2010-11-01
description <p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC). These criteria were further modified in 2004 and became known as the revised Bethesda Guidelines. Our study aimed to retrospectively evaluate the percentage of patients diagnosed with HNPCC tumors in 2004 who met revised Bethesda criteria for MSI testing, who were referred for genetic counseling within our institution.</p> <p>Methods</p> <p>All HNPCC tumors diagnosed in 2004 were identified by accessing CoPath, an internal database. Both the Tumor Registry and patients' electronic medical records were accessed to collect all relevant family history information. The list of patients who met at least one of the revised Bethesda criteria, who were candidates for MSI testing, was then cross-referenced with the database of patients referred for genetic counseling within our institution.</p> <p>Results</p> <p>A total of 380 HNPCC-associated tumors were diagnosed at our institution during 2004 of which 41 (10.7%) met at least one of the revised Bethesda criteria. Eight (19.5%) of these patients were referred for cancer genetic counseling of which 2 (25%) were seen by a genetics professional. Ultimately, only 4.9% of patients eligible for MSI testing in 2004 were seen for genetic counseling.</p> <p>Conclusion</p> <p>This retrospective study identified a number of barriers, both internal and external, which hindered the identification of individuals with HNPCC, thus limiting the ability to appropriately manage these high risk families.</p>
url http://www.hccpjournal.com/content/8/1/9
work_keys_str_mv AT mukherjeeaparna therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT mcgarritythomasj therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT ruggierofrancesca therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT koltunwalter therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT mckennakevin therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT poritzlisa therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT bakermariaj therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT mukherjeeaparna revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT mcgarritythomasj revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT ruggierofrancesca revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT koltunwalter revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT mckennakevin revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT poritzlisa revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
AT bakermariaj revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram
_version_ 1725981740121456640